Revolutionary therapy extends mouse life by up to 35 percent!

Revolutionary therapy extends mouse life by up to 35 percent!

Köln, Deutschland - Researchers of the Max-Planck Institute for Biology of Aging In a groundbreaking study, a combination therapy with the Krebs-Medicaments Rapamycin and tramtinib examined. This therapy could significantly extend the lifespan of mice by about 30 %. The research results show that this combination has more effects than the use of the individual medication.
The use of rapamycin alone extends the lifespan of mice by 15 % to 20 %, while trametinib is 5 % to 16 %. The combination of both drugs even leads to a life extension of up to 35 %, which significantly expands the possibilities of anti-aging medicine.

The study not only outlines the number of years that mice gain the medication, but also emphasizes the positive health effects. Treated mice showed a lower susceptibility to chronic inflammation and a delayed development of cancer. It is particularly noteworthy that the treatment does not affect quality of life - on the contrary, fewer tumors have been found in vital organs such as liver and spleen.

effect of the medication

rapamycin, known for its effect in the MTOR signal path, and trametinib, which modulates the RAS/MEK/Erk-Signalweg, show specific changes in the genetic activity of the mice that could not be observed when taking it alone. These findings are based on a long -term study in which mice were treated with the medication from the age of six months.

The scientists also observed a significant push of typical signs of aging: the heart function and the glucose absorption in the brain remained more stable for treated mice than with control groups. In addition, inflammatory markers in the blood, such as TNF and IL-17A, were reduced, which indicates a reduced inflammatory activity in the organs.

future prospects and clinical studies

The researchers, including Sebastian Grönke, express the hope that these results can soon be tested in clinical studies on humans. A central challenge remains the determination of the optimal dose and an administration of trametinib, which is already approved for humans, which facilitates future studies. However, Prof. Dame Linda Partridge emphasizes that while a lifespan in humans may not be extended to a similar extent, the focus is on staying healthy.

Interest in medication and the area of ​​anti-aging research is increasing worldwide. National Geographic emphasizes that it is a billion dollar business that deals with longevity and improvement in the quality of life in old age. Clinical studies on other anti-aging ingredients are already underway, but so far no experimental preparation that was effective in animal models has reached the market. This is a significant hurdle, but progress in this research could one day influence the reality of the life of many people.

the focus of marginal phenomena has changed towards serious social challenges. With the discoveries from Cologne and the progress in gene research, science on the threshold of possibly revolutionary treatments for a longer, healthy life.